Zealand Pharma A/s

Boehringer Ingelheim International Gmbh

Rasmus Just

Ditte Riber

Dieter Wolfgang Hamprecht

Leo Thomas

Jakob Lind Tolborg

Wolfgang Rist

Keld Fosgerau

Anne Pernille Tofteng Shelton

Pia Nørregaard

Torben Østerlund

Robert Augustin

Lene Jessen

Kirsten Lindegaard Bovbjerg

Wayne Shaun Russell

Kate Hansen

Torben Osterlund

Lise Giehm

Jesper Mosolff Mathiesen

Henrik Kofoed Munch

Maria Alexandrovna Deryabina

Jolanta Skarbaliene

Oliver Demmer

Jesper Sloth Villadsen

Torben ØSterlund

Anne Pernille Shelton

Pia Norregard

Pia NØRREGARD

The present invention relates to compounds which have agonist activity at the glucagon, GIP and GLP-1 receptors, and to their use in the treatment of metabolic disorders.

Glucagon-GLP-1-GIP triple agonist compounds

The present invention relates to amylin analogs and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogs have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.

Amylin analogues

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Glucagon analogues

GLP-2 analogs are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogs are particularly useful for the prophylaxis treatment or ameliorating of the gastro-intestinal associated side effects of diabetes.

Glucagon-like-peptide-2 (GLP-2) analogues

The present invention relates to truncated GIP analogs which comprise one or more substitutions as compared to wild-type GIP and which may have the property of an altered, preferably increased GLP-1 activity, e.g. as assessed in in vitro efficacy assays. The invention provides GIP-GLP-1 dual agonist compounds and associated methods.

GIP-GLP-1 dual agonist compounds and methods

GLP-2 analogs are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogs are particularly useful for the prophylaxis, treatment or ameliorating of the gastro-intestinal associated side effects of diabetes.

Growing community of inventors

Copenhagen, Denmark

Rasmus Just